Results 81 to 90 of about 2,885,121 (322)

Deep-LIBRA: Artificial intelligence method for robust quantification of breast density with independent validation in breast cancer risk assessment [PDF]

, 2020
Breast density is an important risk factor for breast cancer that also affects the specificity and sensitivity of screening mammography. Current federal legislation mandates reporting of breast density for all women undergoing breast screening. Clinically, breast density is assessed visually using the American College of Radiology Breast Imaging ...
arxiv   +1 more source

Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials

Molecular Oncology, EarlyView.
In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.
Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Elin Borgen, Cecilie Bendigtsen Schirmer, Bjørnar Gilje, Øystein Garred, Jon Lømo, Marius Stensland, Oddmund Nordgård, Ragnhild Sørum Falk, Randi R. Mathiesen, Hege G. Russnes, Jon Amund Kyte, Bjørn Naume   +13 more
wiley   +1 more source

A multi-reconstruction study of breast density estimation using Deep Learning [PDF]

arXiv, 2022
Breast density estimation is one of the key tasks in recognizing individuals predisposed to breast cancer. It is often challenging because of low contrast and fluctuations in mammograms' fatty tissue background. Most of the time, the breast density is estimated manually where a radiologist assigns one of the four density categories decided by the ...
arxiv  

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Molecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico van Zandwijk, John E. J. Rasko, Dannel Yeo   +6 more
wiley   +1 more source

A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells were spiked into donor blood to evaluate the recovery rates of the following circulating tumor cell (CTC) enrichment technologies: CellMag™, EasySep™, RosetteSep™, Parsortix® PR1, and Parsortix® Prototype systems. Each method's advantages and disadvantages are described.
Volga M Saini, Ezgi Oner, Mark P. Ward, Sinead Hurley, Brian David Henderson, Faye Lewis, Stephen P. Finn, Gerard J. Fitzmaurice, John J. O'Leary, Sharon O'Toole, Lorraine O'Driscoll, Kathy Gately   +11 more
wiley   +1 more source

RESONANCIA MAGNETICA MAMARIA: INDICACIONES POCO HABITUALES

Revista Chilena de Radiología
Las indicaciones de resonancia magnética mamaria están bien definidas e internacionalmente aceptadas. Se aplican también en Chile según lo establecido en el último Consenso Nacional sobre cáncer mamario, sin embargo observamos que un porcentaje no ...
Paulina González M, Eleonora Horvath P, Patricia Arancibia H, María Galleguillos P, Marcela Jacard C, Alejandra López P, Paulina Neira V, Dulia Ortega T, Miguel Pinochet T, Teresa Taub E, Marcela Uchida S, Heriberto Wenzel K   +11 more
doaj   +1 more source

Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer

New England Journal of Medicine, 2019
Background Patients who have residual invasive breast cancer after receiving neoadjuvant chemotherapy plus human epidermal growth factor receptor 2 (HER2)–targeted therapy have a worse prognosis than those who have no residual cancer.
G. von Minckwitz, Chiun-Sheng Huang, M. Mano, S. Loibl, E. Mamounas, M. Untch, N. Wolmark, P. Rastogi, A. Schneeweiss, A. Redondo, H. Fischer, W. Jacot, A. Conlin, C. Arce‐Salinas, I. Wapnir, C. Jackisch, M. DiGiovanna, P. Fasching, J. Crown, P. Wülfing, Z. Shao, E. R. Caremoli, Haiyan Wu, L. Lam, D. Tesarowski, M. Smitt, Hannah Douthwaite, S. Singel, C. Geyer   +28 more
semanticscholar   +1 more source

Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors

Molecular Oncology, EarlyView.
Cell‐free microRNAs (cfmiRs) are small‐RNA circulating molecules detectable in almost all body biofluids. Innovative technologies have improved the application of cfmiRs to oncology, with a focus on clinical needs for different solid tumors, but with emphasis on diagnosis, prognosis, cancer recurrence, as well as treatment monitoring.
Yoshinori Hayashi, Janelle‐Cheri Millen, Romela Irene Ramos, Jennifer A. Linehan, Timothy G. Wilson, Dave S. B. Hoon, Matias A. Bustos   +6 more
wiley   +1 more source

Leukocytoclastic Vasculitis of the Breast: A Case Report

대한영상의학회지, 2018
Leukocytoclastic vasculitis is a rare disease characterized by neutrophil and immunecomplex deposition in the small vessel walls. We report a 47-year-old female patient with leukocytoclastic vasculitis of the breast, presenting as breast edema on ...
Taeyang Ha, Hyunee Yim, Seon Young Park, Doo Kyoung Kang, Tae Hee Kim   +4 more
doaj   +1 more source

Glycoprotein asporin as a novel player in tumour microenvironment and cancer progression

Biomedical Papers, 2016
Background: Small leucine rich proteoglycans (SLRPs), major non-collagen components of the extracellular matrix (ECM), have multiple biological roles with diverse effects.
Dana Simkova, Gvantsa Kharaishvili, Eva Slabakova, Paul G. Murray, Jan Bouchal   +4 more
doaj   +1 more source